External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
02
11
2022
revised:
02
03
2023
accepted:
09
03
2023
medline:
9
8
2023
pubmed:
20
3
2023
entrez:
19
3
2023
Statut:
ppublish
Résumé
Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ≤15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification. It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan-Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching. After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP≤15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP≤15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated. the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients.
Sections du résumé
BACKGROUND
Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ≤15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification.
METHOD
It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan-Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching.
RESULTS
After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP≤15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP≤15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated.
CONCLUSION
the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients.
Identifiants
pubmed: 36935222
pii: S0748-7983(23)00377-3
doi: 10.1016/j.ejso.2023.03.206
pii:
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1488Investigateurs
B Rufián-Andújar
(B)
F Valenzuela-Molina
(F)
A Casado-Adam
(A)
J M Sánchez-Hidalgo
(JM)
S Rufián-Peña
(S)
R Ortega-Salas
(R)
M Granados-Rodríguez
(M)
M C Vázquez-Borrego
(MC)
F I Bura
(FI)
J P Castaño
(JP)
S Kusamura
(S)
D Baratti
(D)
M Guaglio
(M)
Pascual A Angel Castaño
(PA)
Ruiz de Valbuena Bueno C
(R)
F Quénet
(F)
S Yilmaz
(S)
Torun B Canbay
(TB)
E Sola Vendrell
(E)
L González-Bayón
(L)
W Ceelen
(W)
W Willaert
(W)
J Demuytere
(J)
M E Alberto-Vilchez
(ME)
S Gül-Klein
(S)
Glehen Olivier
(G)
Isabelle Bonnefoy
(I)
Cecile Odin
(C)
Laurent Villeneuve
(L)
Sylvie Isaac
(S)
Nazim Benzerdjeb
(N)
Juliette Fontaine
(J)
Philippe Bertheau
(P)
Maysoun Kassem
(M)
Isabelle Sourrouille
(I)
Maximiliano Gelli
(M)
Charles Honore
(C)
Peggy Dartigues
(P)
Valérie Boige
(V)
Véroniques Verriele
(V)
Cécile Brignad
(C)
Gerlinde Averous
(G)
C Shields
(C)
J Aird
(J)
Antonio Scapinello
(A)
Maria Chiara Biatta
(MC)
Marco Tonello
(M)
Chiara Cenzi
(C)
Informations de copyright
Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.